Clinical Trial Update: Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval [Phase 1]

View source ↗

Summary

Phase 1 trial assessing placebo-corrected QT/QTc effects of ITF2357 (Givinostat) at therapeutic and supratherapeutic doses alongside moxifloxacin; results compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Becker Muscular Dystrophy
• Duchenne Muscular Dystrophy
• Polycythemia Vera

Drugs mentioned

• ITF2357 (givinostat) (givinostat)
• Moxifloxacin (moxifloxacin)

Snippet

Sponsor: Italfarmaco | Conditions: Duchenne and Becker Muscular Dystrophy, Polycytemia Vera | Phase 1 | Status: COMPLETED | Results posted: 2024-01-11